The Herald was informed last week of a 15-year-old special-needs Chaparral High School student who is in need of a kidney ...

Morgans healthcare and life sciences experts Iain Wilkie and Scott Power give Stockhead readers their top picks for 2025.

J.P. Morgan’s U.S. equity analysts picked their top stocks for 2025 in healthcare, selecting “the most compelling investment ...

But like some others on this list, its debut was merely an entrée. A larger opportunity lies ahead, the rare kidney disease FSGS, or focal segmental glomerulosclerosis. Filspari in FSGS would be a ...

Travere Therapeutics' financial landscape is a mix of FDA approvals, clinical setbacks, and cash concerns, with potential for growth and revenue.

The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Professor ...

ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies.- Inflammasome ASC Inhibitor IC 100 ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December ...

Inaxaplin is under development for the treatment of APO-L1 mediated kidney diseases including focal segmental glomerulosclerosis (FSGS). The drug candidate is administered through oral route. It acts ...

Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by ...

Treatment was based on corticosteroids alone followed by immunosuppressants with no significant difference (p = 0.82). Partial remission was noted in 9 patients with LGM, i.e. 69.2%, and total ...